Indaptus Therapeutics completes $24 million private placement

Indaptus Therapeutics, Inc. completed a private placement on October 16, 2026, receiving the full purchase price from investors in accordance with the terms of the amended Stock Purchase Agreement. The company issued an aggregate of 20,338,974 shares of common stock to the purchasers, generating gross proceeds of approximately $24.0 million before deducting offering expenses.

The transaction follows a Stock Purchase Agreement dated September 8, 2026, which Indaptus Therapeutics first disclosed in a Form 8-K filed with the Securities and Exchange Commission on September 9, 2026. The agreement obligated the company to issue and sell the shares to designated purchasers. Initially, the outside date for the transaction was set for September 29, 2026. However, as reported in a subsequent Form 8-K filed on September 30, 2026, the company and the purchasers entered into notices and consents that extended this deadline to October 16, 2026.

The closing of the private placement was signed by Junyi Dai, Chief Executive Officer of Indaptus Therapeutics, on October 20, 2026. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the ticker symbol INDP. Its principal executive offices are located at 3 Columbus Circle, 15th Floor, New York, New York 10019.